Anna L de Goede1, Arno C Andeweg2, Henk-Jan van den Ham3, Maarten A Bijl4, Fatiha Zaaraoui-Boutahar5, Wilfred F J van IJcken6, Sofie Wilgenhof7, Joeri L Aerts8, Rob A Gruters9, Albert D M E Osterhaus10. 1. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands; Department of Hospital Pharmacy, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: anna.degoede@radboudumc.nl. 2. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: a.andeweg@erasmusmc.nl. 3. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: hj.vandenham@erasmusmc.nl. 4. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: m.a.bijl@erasmusmc.nl. 5. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: f.zaaraoui@erasmusmc.nl. 6. Erasmus Center for Biomics, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: w.vanijcken@erasmusmc.nl. 7. Department of Medical Oncology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium; Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. Electronic address: sofie.wilgenhof@vub.ac.be. 8. Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. Electronic address: joeri.aerts@vub.ac.be. 9. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: r.gruters@erasmusmc.nl. 10. Department of Viroscience, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Electronic address: a.osterhaus@erasmusmc.nl.
Abstract
OBJECTIVE: This study aimed to evaluate the effect of dendritic cell (DC) vaccination against HIV-1 on host gene expression profiles. DESIGN: Longitudinal PBMC samples were collected from participants of the DC-TRN trial for immunotherapy against HIV. Microarray-assisted gene expression profiling was performed to evaluate the effects of vaccination and subsequent interruption of antiretroviral therapy on host genome expression. Data from the DC-TRN trial were compared with results from other vaccination trials. METHODS: We used Affymetrix GeneChips for microarray gene expression analysis. Data were analyzed by principal component analysis and differential gene expression was assessed using linear modeling. Gene ontology enrichment and gene set analysis were used to characterize differentially expressed genes. Transcriptome analysis included comparison with PBMCs obtained from DC-vaccinated melanoma patients and of healthy individuals who received seasonal influenza vaccination. RESULTS: DC-TRN immunotherapy in HIV-infected individuals resulted in a major shift in the transcriptome. Longitudinal analysis demonstrated that changes in the transcriptome sustained also during interruption of antiretroviral therapy. After DC-vaccination, the transcriptome was enriched for cellular immunity associated genes that were also induced in healthy adults who received live attenuated influenza virus vaccination. These beneficial responses were accompanied by detrimental signals of general immune activation. CONCLUSIONS: The DC-TRN induced changes in the transcriptome were profound, lasting, and consisted of both protective signals and signatures of inflammation and immune exhaustion, with a net result of decreased viral load, without clinical benefit. Thus transcriptome analysis provides useful information, dissecting both positive and negative effects, for the evaluation of safety and efficacy of immunotherapeutic strategies.
OBJECTIVE: This study aimed to evaluate the effect of dendritic cell (DC) vaccination against HIV-1 on host gene expression profiles. DESIGN: Longitudinal PBMC samples were collected from participants of the DC-TRN trial for immunotherapy against HIV. Microarray-assisted gene expression profiling was performed to evaluate the effects of vaccination and subsequent interruption of antiretroviral therapy on host genome expression. Data from the DC-TRN trial were compared with results from other vaccination trials. METHODS: We used Affymetrix GeneChips for microarray gene expression analysis. Data were analyzed by principal component analysis and differential gene expression was assessed using linear modeling. Gene ontology enrichment and gene set analysis were used to characterize differentially expressed genes. Transcriptome analysis included comparison with PBMCs obtained from DC-vaccinated melanomapatients and of healthy individuals who received seasonal influenza vaccination. RESULTS: DC-TRN immunotherapy in HIV-infected individuals resulted in a major shift in the transcriptome. Longitudinal analysis demonstrated that changes in the transcriptome sustained also during interruption of antiretroviral therapy. After DC-vaccination, the transcriptome was enriched for cellular immunity associated genes that were also induced in healthy adults who received live attenuated influenza virus vaccination. These beneficial responses were accompanied by detrimental signals of general immune activation. CONCLUSIONS: The DC-TRN induced changes in the transcriptome were profound, lasting, and consisted of both protective signals and signatures of inflammation and immune exhaustion, with a net result of decreased viral load, without clinical benefit. Thus transcriptome analysis provides useful information, dissecting both positive and negative effects, for the evaluation of safety and efficacy of immunotherapeutic strategies.
Authors: Edione C Reis; Lais T da Silva; Wanessa C da Silva; Alexandre Rios; Alberto J Duarte; Telma M Oshiro; Sergio Crovella; Alessandra Pontillo Journal: Hum Vaccin Immunother Date: 2018-05-17 Impact factor: 3.452
Authors: Antonio Victor Campos Coelho; Ronald Rodrigues de Moura; Anselmo Jiro Kamada; Ronaldo Celerino da Silva; Rafael Lima Guimarães; Lucas André Cavalcanti Brandão; Luiz Cláudio Arraes de Alencar; Sergio Crovella Journal: Int J Mol Sci Date: 2016-11-26 Impact factor: 5.923
Authors: Henk-Jan van den Ham; Jason D Cooper; Jakub Tomasik; Sabine Bahn; Joeri L Aerts; Albert D M E Osterhaus; Rob A Gruters; Arno C Andeweg Journal: PLoS One Date: 2018-02-01 Impact factor: 3.240
Authors: Shikhar Mehrotra; Carolyn D Britten; Steve Chin; Elizabeth Garrett-Mayer; Colleen A Cloud; Mingli Li; Gina Scurti; Mohamed L Salem; Michelle H Nelson; Melanie B Thomas; Chrystal M Paulos; Andres M Salazar; Michael I Nishimura; Mark P Rubinstein; Zihai Li; David J Cole Journal: J Hematol Oncol Date: 2017-04-07 Impact factor: 17.388
Authors: Roque Pastor-Ibáñez; Francisco Díez-Fuertes; Sonsoles Sánchez-Palomino; Jose Alcamí; Montserrat Plana; David Torrents; Lorna Leal; Felipe García Journal: Vaccines (Basel) Date: 2021-06-24